
PMC:7600245 / 17160-17542
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T64 | 328-336 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T156 | 15-16 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T157 | 29-34 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T158 | 142-143 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T176 | 29-34 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T177 | 114-123 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T178 | 135-138 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
T179 | 145-154 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T180 | 160-179 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T181 | 160-169 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T182 | 170-179 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T183 | 205-224 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T184 | 205-214 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T185 | 215-224 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T26 | 290-304 | http://purl.obolibrary.org/obo/GO_0019076 | denotes | viral shedding |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T128 | 0-382 | Sentence | denotes | Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]. |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
420 | 337-345 | Species | denotes | patients | Tax:9606 |
429 | 145-154 | Chemical | denotes | ribavirin | MESH:D012254 |
430 | 160-179 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
431 | 205-224 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
434 | 328-336 | Disease | denotes | COVID-19 | MESH:C000657245 |